Related Experiment Video
Updated: Jul 2, 2026
10:28
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Ribavirin targets eIF4E dependent Akt survival signaling
Keith Tan1, Biljana Culjkovic, Abdellatif Amri
1Institute for Research in Immunology and Cancer, Department of Pathology and Cell Biology, Université de Montréal, Montréal, Que., Canada H4M 1J6.
Biochemical and Biophysical Research Communications
|August 19, 2008
Summary
Ribavirin, a cap mimic, inhibits cancer-driving eIF4E activity by blocking 7-methyl guanosine cap binding. This disrupts Akt survival signaling and rescues apoptosis, offering a new cancer treatment strategy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The eukaryotic translation initiation factor 4E (eIF4E) is crucial for cancer cell survival and proliferation.
- eIF4E regulates the expression of genes involved in Akt-dependent survival signaling pathways.
- eIF4E's function relies on binding to the 7-methyl guanosine (m(7)G) cap structure at the 5'-end of messenger RNAs (mRNAs).
Purpose of the Study:
- To investigate the potential of m(7)G cap mimics to inhibit eIF4E activity in cancer.
- To determine if ribavirin, an m(7)G cap mimic, can impede eIF4E-mediated Akt survival signaling.
- To explore ribavirin's therapeutic potential in targeting eIF4E-dependent cancers.
Main Methods:
- Utilized ribavirin as a physical mimic of the m(7)G cap.
- Assessed the impact of ribavirin on eIF4E-dependent Akt activation and upstream signaling molecules, including NBS1.
- Evaluated the effect of ribavirin on eIF4E-dependent apoptotic rescue.
- Compared the effects of ribavirin with a non-mimicking analog, tiazofurin.
Main Results:
- Ribavirin effectively inhibits eIF4E-dependent Akt survival signaling by impairing Akt activation.
- Ribavirin reduces the production of NBS1, an upstream activator of Akt.
- Ribavirin treatment leads to the impairment of eIF4E-dependent apoptotic rescue.
- Tiazofurin, lacking m(7)G cap mimicry, did not inhibit eIF4E activity, confirming the mechanism of action.
Conclusions:
- Ribavirin acts as a first-in-class inhibitor of eIF4E-dependent cancers by competing for m(7)G cap binding.
- Ribavirin coordinately disrupts multiple eIF4E-dependent pathways, leading to potent inhibition of cancer cell survival.
- This study establishes a novel therapeutic strategy targeting eIF4E in cancer treatment.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:51Mechanisms of Retrovirus-induced Cancers
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...